KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Equity Average (2016 - 2025)

Historic Equity Average for Halozyme Therapeutics (HALO) over the last 15 years, with Q3 2025 value amounting to $418.3 million.

  • Halozyme Therapeutics' Equity Average rose 1273.85% to $418.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $418.3 million, marking a year-over-year increase of 1273.85%. This contributed to the annual value of $223.8 million for FY2024, which is 7650.57% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Equity Average stood at $418.3 million, which was up 1273.85% from $407.5 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Equity Average peaked at $423.0 million during Q1 2025, and registered a low of $93.7 million during Q2 2021.
  • Its 5-year average for Equity Average is $234.9 million, with a median of $200.7 million in 2021.
  • In the last 5 years, Halozyme Therapeutics' Equity Average tumbled by 6081.09% in 2023 and then soared by 22340.95% in 2025.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Equity Average stood at $239.3 million in 2021, then tumbled by 44.26% to $133.4 million in 2022, then increased by 24.81% to $166.5 million in 2023, then surged by 145.21% to $408.3 million in 2024, then grew by 2.47% to $418.3 million in 2025.
  • Its Equity Average was $418.3 million in Q3 2025, compared to $407.5 million in Q2 2025 and $423.0 million in Q1 2025.